Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Fleming

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Plos One|December 19, 2013
Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemicHelen K Green, Nick Andrews, Douglas Fleming, et al.
Emerging Infectious Diseases|May 18, 2006
1951 influenza epidemic, England and Wales, Canada, and the United StatesCécile Viboud, Theresa Tam, Douglas Fleming, et al.
Clinical Interventions in Aging|April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitusChetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Current Medical Research and Opinion|February 9, 2012
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminAnthony H Barnett, Bernard Charbonnel, Mark Donovan, et al.
Postgraduate Medicine|June 18, 2011
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetesChetan Karyekar, Mark Donovan, Elsie Allen, et al.
Influenza and Other Respiratory Viruses|October 10, 2013
Effectiveness of seasonal influenza vaccine in preventing medically attended influenza infection in England and Wales during the 2010/2011 season: a primary care-based cohort studyGeorge Kafatos, Richard Pebody, Nick Andrews, et al.
Emerging Infectious Diseases|October 19, 2005
Potential impact of antiviral drug use during influenza pandemicRaymond Gani, Helen Hughes, Douglas Fleming, et al.
Vaccine|June 30, 2006
Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemicCécile Viboud, Theresa Tam, Douglas Fleming, et al.
Clinical Drug Investigation|August 17, 2013
Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacyAnthony H Barnett, Bernard Charbonnel, Jia Li, et al.
The Journal of Infection|December 3, 2013
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policyDeborah Cromer, Albert Jan van Hoek, Mark Jit, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Plos One|December 19, 2013
Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemicHelen K Green, Nick Andrews, Douglas Fleming, et al.
Emerging Infectious Diseases|May 18, 2006
1951 influenza epidemic, England and Wales, Canada, and the United StatesCécile Viboud, Theresa Tam, Douglas Fleming, et al.
Clinical Interventions in Aging|April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitusChetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Current Medical Research and Opinion|February 9, 2012
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminAnthony H Barnett, Bernard Charbonnel, Mark Donovan, et al.
Postgraduate Medicine|June 18, 2011
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetesChetan Karyekar, Mark Donovan, Elsie Allen, et al.
Influenza and Other Respiratory Viruses|October 10, 2013
Effectiveness of seasonal influenza vaccine in preventing medically attended influenza infection in England and Wales during the 2010/2011 season: a primary care-based cohort studyGeorge Kafatos, Richard Pebody, Nick Andrews, et al.
Emerging Infectious Diseases|October 19, 2005
Potential impact of antiviral drug use during influenza pandemicRaymond Gani, Helen Hughes, Douglas Fleming, et al.
Vaccine|June 30, 2006
Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemicCécile Viboud, Theresa Tam, Douglas Fleming, et al.
Clinical Drug Investigation|August 17, 2013
Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacyAnthony H Barnett, Bernard Charbonnel, Jia Li, et al.
The Journal of Infection|December 3, 2013
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policyDeborah Cromer, Albert Jan van Hoek, Mark Jit, et al.
Pageof 4